Company intelligence / Profile preview

Maxwell Plus

Brisbane, Queensland, Australiacbinsights.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Maxwell Plus developed an AI-driven platform that combined machine vision and expert clinicians to improve early detection of prostate cancer. Their technology analyzed blood tests and MRI scans to identify cancers missed by standard methods. The company demonstrated improved diagnostic rates—more than double current clinical practice—but failed to achieve sustainable business growth or secure sufficient investment before shutting down in 2023.

Therapeutic areas: OncologyNeurology
Modalities: DeviceNon-pharmacological therapyArtificial intelligence-based diagnostics
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Maxwell Plus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxwell Plus.

Explore the full profile